Preliminary New Evidence Update

PDF cover

PCSK9 Inhibitors: Preliminary New Evidence Update

This Preliminary New Evidence Update for PCSK9 inhibitor alirocumab (Praluent®, Regeneron/Sanofi) incorporates results from the ODYSSEY outcomes trial presented at the American College of Cardiology’s 2018 Scientific Session. Under ICER’s established protocols for accepting in-confidence data, an agreement with Regeneron and Sanofi allowed ICER to evaluate the new evidence and, working with a team of academic faculty from the University of California, San Francisco, to update its cost-effectiveness analyses and associated value-based price benchmarks for this drug.


View All Materials on this Topic or Go Back to View More Materials